Personalis (NASDAQ:PSNL) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Personalis (NASDAQ:PSNL) from a hold rating to a strong sell rating in a research note released on Tuesday,Zacks.com reports.

A number of other research firms have also commented on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Needham & Company LLC lowered Personalis from a “buy” rating to a “hold” rating in a research report on Monday. Lake Street Capital cut Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research note on Monday. Finally, TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $14.25.

Personalis Trading Down 2.0%

Shares of NASDAQ:PSNL opened at $12.22 on Tuesday. Personalis has a 1-year low of $3.84 and a 1-year high of $16.39. The stock has a market capitalization of $1.28 billion, a P/E ratio of -11.98 and a beta of 2.24. The business has a 50-day moving average price of $11.47 and a two-hundred day moving average price of $9.04.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. As a group, equities analysts predict that Personalis will post -1.07 EPS for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock worth $5,599,929 in the last ninety days. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Personalis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. T. Rowe Price Investment Management Inc. grew its stake in Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after buying an additional 861,948 shares during the last quarter. Finally, Next Century Growth Investors LLC acquired a new stake in shares of Personalis in the 4th quarter valued at approximately $4,970,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.